An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

Whatever your thoughts on weight-loss injections, their rise shows no signs of slowing. And now a Dubai restaurant has become ...

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

Lilly's daily obesity pill, orforglipron, shows positive results in late-stage trial, with patients losing nearly 12% of body ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

Men with T2D who initiate SGLT2 inhibitors vs GLP-1 RAs face an almost twofold elevated risk for phimosis after a year of ...